Truncated cone heart valve stent

Information

  • Patent Grant
  • 9095433
  • Patent Number
    9,095,433
  • Date Filed
    Tuesday, October 18, 2011
    13 years ago
  • Date Issued
    Tuesday, August 4, 2015
    9 years ago
Abstract
A heart valve stent having a section with a heart valve implant and several proximally disposed tissue anchors, also comprising a plurality of anchoring threats, each with a proximate end fastened to the stent or valve and a distal end attached to tissue within a heart chamber to provide tension between the heart chamber tissue and the stent.
Description
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

No federal government funds were used in researching or developing this invention.


BACKGROUND
Field of Invention

The invention refers to a valve stent with a section equipped to receive a heart valve implant and several of proximally disposed anchoring elements.


Such heart valve stents are known in various forms for the replacement dysplastic and degenerated heart valves. Thereby, the surgical implantation of heart valve prostheses is regularly accomplished in the cardioplegic heart. The old, functionally degenerated heart valve is resected and the new, implantable heart valve is sewed in.


However, when the mitral valve is affected, one tries, as far as possible, to maintain the old valve in spite of its malfunctioning so that the entire dynamic mitral valve apparatus is not disturbed. The reason for this is that, for instance, the chordae tendineae, which are attached to the mitral valve are very important for ventricular function. Therefore, they should preferably not be removed from the old mitral valve.


Ideally, the mitral valve (in case the old valve cannot be reconstructed) will be pushed aside as far as possible to make room for a new valve. Space does not play such an important role as compared to the aortic annulus which can be more easily stenosed (i.e., during displacement of the old aortic valve for sole percutaneous implantation).


The chordae tendineae of the mitral valve shall be, if possible, structurally maintained to preserve the ventricular geometry and hence of the left ventricle or achieve optimal function of the left chamber as far as possible. Therefore, a best possible function of the left chamber is obtained and achieved. Of significant relevance is that the anterior mitral valve leaflet is not pushed aside into the free space toward the left ventricle, but rather that it is attached to the mitral annulus so that a press forward of the anterior leaflet into the left ventricular outflow tract (LVOT) is avoided (“sam” phenomenon: systolic anterior movement). This is extremely important, because otherwise a left heart decompensation (massive dysfunction of the left ventricle) could rapidly occur.


Surgically the old mitral valve is attached to the old annulus so that there is a free flow of blood through the valve and both adjacent heart chambers. After pushing aside (attachment of the valve onto the annulus) the heart valve prosthesis is surgically implanted into the annulus.


This extensive method mandatorily takes place with the help of a heart- and lung-machine. For high risk patients it is usually not used and minimally invasive and percutaneous methods to perform the implantation of a heart valve are sought.


In this context, the German patent DE 195 46 692 C2 and the corresponding EP 1 469 797 B1 is known. This patent describes a self-expanding heart valve prosthesis for the implantation into a human body using a catheter system with a heart valve and a foldable, valve-connected and expanding stent. Such a self-expanding heart valve prosthesis can be directed through the femoral artery with the help of a catheter based system to the area of cardiac implantation. After the stent reaches the area of implantation, it can be successively unfolded. Along its long axis, the stent is composed of several, at angles to each other, self-expanding segments that are unfolded gradually. After expansion, the heart valve prosthesis can be anchored with the support of hooks at least in the respective blood vessel close to the heart.


Another apparatus for the fixation and anchorage of heart valve prostheses is described in the German Patent 100 10 074 A1 which fundamentally consists of wire-like elements attached together. Different brackets are hereby used to secure anchorage and brace a heart valve.


Even with the known solutions there is still the danger that a heart valve will be incorrectly implanted due to wrong positioning and deficient angular adjustment of the heart valve prosthesis.


Improved positioning and angular alignment for the aortic valve can be reached by the stent described in the European Patent EP 1 469 797 B1 which consists of supportive holders which can be inserted into the aortic pouches and create a defined distance to the aortic valve. Beyond this, the possibility exists to halt a failed implantation of a heart valve prosthesis and to push the valved stent (“a valve integrated into a stent”) back into the catheter delivery system (more precisely the “cartridge”). Thereby, it is possible that the stent can again slide out when good positioning for the valved stent has been reached. Thus, the valved stent can be taken in and out until the optimal positioning has been achieved (“sliding technique”).


A much larger problem for the optimal positioning of the new heart valve in the stent (alternatively valved stent) still exists in the following: in most cases the old, native valve will not be eliminated by the above-described technique of implantation.


This leads to the fact that the new valve which will be pressed into (partly squashed into) the old, deformed valve will be transformed into the original form. The reason for this is that the location of implantation for the valved stent is affected by the morphology, the shape and consistency of the old native valve (for instance by sclerosis or calcification of the native valve).


Therefore, the old annulus of the valve with the corresponding changed valves pouches determines to what extent and where the native valve will unfold and whether its form can develop. Hence, for the optimal function of the valve and maintenance of the atrial and ventricular function not only the anchorage/positioning is important, but also the fitting of the valve stent into the neo-annulus (old valve annulus with old valve shapes it) and with it the pushing back of the old valve.


Based on the fact that there are known problems of the valved stents, the challenge of this intervention is to produce a heart valved stent, especially a mitral valved stent, for minimally-invasive transplantation, which preferably facilitates the natural functioning of the heart.


Referring to the invention, this problem will be solved with the heart valved stent and its features from claim 1. The subclaims provide advantageous designs for setting up the intervention.


The basic idea of the invention is to produce a heart valve stent which establishes the anatomic requirements for the natural exertion of the function—like a healthy heart. In the process, the invention-related heart valve stent with its self-expanding, foldable embodiment establishes a minimally-invasive operation which assures an exact positioning and secure fixation of the valve stent. Thereby, a tension between the mitral valve and ventricle similar to the natural tension of the chordae tendineae is generated, and at the same time it will be provided that the valve parts of the old mitral valve (especially the anterior mitral valve leaflet) will not disturb the flow rate of the blood.


Therefore, it is intended that the valve stent, according to the invention, is catheter-inserted into one of the heart chambers or into the adjacent large vessels of the heart, then unfolded in one of the heart chambers, whereupon its anchoring elements are fixed in the tissue. Finally, the stent is fixed at its opposed, subvalvular wall of the heart chamber under development of a tension between the wall of the heart chamber and the proximal, supravalvular, fixed anchoring elements with anchoring sutures (hereafter referred to as neo-chordae).


The fixation of the anchoring sutures in the distal wall of the heart chamber exhibits a thrust bearing to the proximal anchoring elements which will be established by a joint or another element acting as a thrust bearing. This counter bearing can be preferentially designed also as an adjusting element for the length of the sutures.


Advantages of the heart valve stents which according to the intervention are the exact and easy fixation of the heart valve stent and improved contractility of the heart in minimally invasive operations in comparison with customary valve stents.


Preferentially, the axially, relatively to the longitudinal axis, arranged anchoring sutures are fixed according to the invention (the valve stent) with one end to the annulus of the heart valve implant, so that after development of a tension between the stent and the wall of the ventricle, the positioning and the angular arrangement of the valve can be directly impacted. The anchoring sutures can also be fixed at the distal part of the circumference of the valve stent. The connection between the anchoring sutures and the stent has to be conducted so that a tension which should run fundamentally in an axial direction relative to the long axis of the stent and is formed between the proximal anchoring elements and the distal counter bearing.


According to another preferential design of the invention, the anchoring sutures (neo-chordae) have elements to adjust the length of the anchoring sutures so that through the length of the anchoring sutures a certain tension between the heart valve stent and the heart wall can be regulated.


Thereby, an adjusting element, for example, for the individual length of sutures or for all sutures together can be allowed for. The adjusting element for the length of sutures is preferably designed small and can, for instance, be constructed in such a manner that this element shortens the suture to the desired length by rolling up the excess thread.


The construction of the elastic anchoring sutures along the axis are also preferred so that they are able to react to heart contractions without having too sutures that might negatively affect the heart function. Here the suture length should be selected so that the elasticity is not sacrificed due to the tension between the anchoring elements and the heart wall.


After adjusting the counter bearing of the adjusting element to the length of sutures, a notably beneficial design is made so that also a re-adjustment of the tension between the anchoring elements and the counter bearing, i.e. a re-tensioning of the anchoring sutures is possible without opening the heart.


Especially favored is the structure of the mitral valve stent which is fundamentally oval or u-shaped in the plane of the mitral valve annulus so that no pressure to the LVOT (left ventricular outflow tract) and/or aortic annulus is exerted. Therewith damage to the hearts function is stopped (Ma L, Tozzi P, Huber C H, Taub S, Gerelle G, von Segesser L K. Double-crowned valved stents for off-pump mitral valve replacement. Eur J Cardiothorac Surg. 2005 August; 28 (2):194-8; discussion 198-9.). Additionally, the subvalvular apparatus also completely retains its natural anatomy and is not compromised (Boudjemline Y, Agnoletti G, Bonnet D, Behr L, Borenstein N, Sidi D, Bonhoeffer P. Steps toward the percutaneous replacement of atrioventricular valves, an experimental study. J Am Coll Cardiol. 2005 Jul. 19; 46 (2)i360-5).


This valve stent has for the natural mitral valve apparatus a completely adapted, exceedingly nestled form so that this conically tapered (cranial-caudal axis) not entirely circular (oval-like in the transversal axis) valve stent is able to attach to and abut to the natural form of the mitral valve. In the area of the anterior mitral valve annulus, the valve stent is flat and exerts almost no pressure on and does not constrict the LVOT. In the area of the posterior mitral valve annulus, it is oval and replicates a form like the posterior annulus. This valve stent forms a thin, restricted along the length (cranial-caudal) structure which in its form aligns completely to the mitral valve and thus in the area of the natural mitral valve annulus looks like a negative impression of it. In fact, the valve stent contacts the old mitral valve and the annulus, but leaves their anatomy completely unchanged.





In the following the invention will be closely elucidated by means of the attached figures representing the particularly preferred execution examples. It shows:



FIG. 1 a favored execution example of the valve stent according to the invention in a schematic lateral view;



FIG. 2 the demonstrated execution example in FIG. 1 with top view from above;



FIG. 3 top view on several especially preferred valve stents according to the invention;



FIG. 4 a top view from an execution example from below;



FIG. 5 a schematic view which explains the minimally-invasive transplantation of the mitral valve stent according to the invention in a first phase of insertion of the mitral valve stent into the location of transplantation;



FIG. 6 a schematic view for the demonstration of the minimally-invasive transplantation of the mitral valve stents according to the invention in a second phase after positioning of the mitral valve;



FIG. 7 a schematic view for demonstration of the minimally invasive transplantation of the mitral valve stent after completion of the fixation of the anchoring sutures outside of the apex of the ventricular heart wall;



FIG. 8 a schematic view of an alternative, intra-cardiac fixation of the anchoring sutures in the area of papillary muscles;



FIG. 9 a schematic view of a heart valve stent which is fixed in the aortic annulus according to the invention;



FIG. 10 a schematic view of a heart valve stent which is fixed in the pulmonary position according to the invention;



FIG. 11 a schematic view of a heart valve stent which is fixed in the tricuspid position according to the invention;



FIG. 12 an especially preferred execution example of the valve stent (according to the invention) in a schematic lateral view without heart valve and anchoring sutures; and



FIG. 13 a schematic dorsal, intra-cardiac view of a heart valve stent which is fixed in the mitral position according to the invention.






FIGS. 1 to 11 indicate the stent according to the invention for the implantation and fixation of heart valve prostheses in different views to show the configuration of the stents and the spatial relations of individual parts of the stent to each other in an unfolded (FIGS. 1-4 and 6-11) and in a folded condition (FIG. 5).



FIG. 1 shows a foldable mitral valve stent 10 according to the invention in a perspective lateral view. The stent 1-0 exhibits mainly three parts: proximally (supravalvularly) on stent 10 there are several serrated, arched anchoring (FIG. 3) elements circularly arranged which are able to anchor supravalvularly (respectively atrially) the valve stent 10 in an implanted condition. The preferable stent body 30 flattened to the LVOT is distally adjoined and is conical and in cross section ovally shaped (compare FIG. 2).


The stent body 30 forms a basket- or trapezoid-like figure which nestles to the mitral valve annulus and extends in the direction of the left ventricle. This stent 10 is held in the atrium due to its conically-tapered form and due to the atrial anchoring elements 20. A bi- or tri-leaflet valve 50 can be integrated into the stent body 30.


At the distal part of the stent body 30 (to the direction of the left ventricle) there are anchoring sutures 40 which are distally equipped to the stent body 30 for the anchorage of the entire stent 10. These anchoring sutures 40 provide for an anchorage in the opposed wall of the ventricle or for instance in the area of the papillary muscles 30 (proximal, medial or distal part of the papillary muscle); compare FIGS. 7 and 8. With the help of a adjusting element to regulate the length of sutures 70, these anchoring sutures 40 can be positioned and adjusted to the optimal length so that the heart valved stent 10 can be fixed and anchored.



FIG. 2 indicates the stent 10 in a top view. Thereby, it can be distinguished that stent 10 forms a neo-annulus, alternatively a stent body 30 in which the heart valve prosthesis 50 can be implanted and in which it can be fixed. Furthermore, it can be recognized that the invention-like stent 10 can be shaped asymmetrically in relation to several supravalvular (atrial) stent brackets 20.


This can be identified by the fact that the stent body 30 is oval-like and flattened on one side as seen in this figure, so it (the stent body 30) can be installed with its flattened side towards the direction of the LVOT. This flattening has the consequence that no pressure on this side towards the LVOT and towards the aortic valve can be exerted from the self-expanding stent in case the stent 10 is used, i.e. in the mitral position. Further favored embodiments of the stent 10 are indicated in FIG. 3 according to the invention.



FIG. 4 demonstrates the invention-pertaining stent 10 from a bottom view. From this it is obvious that the diameter of the atrial part to the ventricular part of the stent body 30 becomes smaller so that this looks like a truncated cone from the lateral view (compare FIG. 1). The anchoring elements 20 as well as the stent body 30 can be upholstered with cloth (i.e. synthetics, pericardium, PTFE or Goretex, etc.) to achieve better sealing between the heart valve prosthesis 50, stent body 30 and the surrounding heart structure. This sealing membrane is tapered/alternatively upholstered between the heart valve prosthesis 50, the stent body 30 or onto the atrial stent struts 20 to achieve optimal sealing of the valve between both heart chambers.


In FIGS. 5 to 7 and 8, the retrograde trans-apical implantation of the valved stent is described. The retrograde trans-aortic as well as the antegrade trans-atrial approach can stent above the old mitral annulus is shown in FIG. 5. A slow unfolding (preferred self-expanding) of the atrial anchoring elements 20 can be started after successful orientation with support of labeling at the valve stent 10 (not shown). The positioning in the left atrium should be done in that way that the flattened side of the stent body 5 is turned towards the direction of the LVOT (aortic valve). The stent will be further expanded.



FIG. 6 indicates the expanded valve stent 10 in the left-atrio-ventricular in-flow tract. Anchoring sutures 40 are adjusted in or outside the wall of the heart and later—as shown in FIG. 7—they will be fixed with the support of the thrust bearing 80 which is favorably designed as an adjusting element for the length of sutures. During the adjustments for the length of the anchoring sutures 40, visualization of the mitral valve apparatus (i.e. Echo, CT, NMR) is carried out so as to optimally pull the annulus of the new stent 10 toward the ventricular wall, paravalvular leakage no longer exists, the stent 10 can be fixed in a good manner, and the mitral valve annulus and—apparatus support advantageously the left ventricular function.


Alternatively to FIG. 7, the anchoring sutures 40 can also be fixed at the papillary muscles (see FIG. 8) so that these sutures 40 represent the neo chordae and take 20 over the function of the functionless chordae tendineae. The fixation of the anchoring sutures 40 at the wall of the heart in each case result from a thrust bearing 80 which can be developed as a knot or also as an independent element. It is also possible that the ventricular anchoring sutures 40 are not only affixed to the stent body 30, but also at the integrated valve itself. The caudal anchoring sutures 40 can also be fixed at any other point of the ventricle.



FIG. 7 shows the accomplished positioning and fixation of the stent 10. After the length and location of the single anchoring sutures 40 has been determined, these anchoring sutures 40 will be fixed with the suture-length adjusting elements 70, for instance, in the left ventricular wall. The suture-length adjusting element 70 is used for the optimal calibration of the length and position of the valve stent 10 and therefore for the valve prosthesis 50. Different sutures 40 can exhibit different length and fixing positions in the ventricle.



FIGS. 9 to 11 demonstrate additional examples for the application of the valve stent 10 according to the invention, whereas the stent 10 is readjusted to the particular anatomy (for the aortic- and pulmonary valve position a rather circular form (compare FIG. 3) and for the tricuspid position a rather oval form).



FIG. 12 shows an especially preferred designed execution example of the valve stent pertaining to the invention in a schematic lateral view which is shown without heart valve and anchoring sutures for a better clearness. For clarification in FIG. 12 of the positioning of the valve stent in situ, FIG. 13 demonstrates a schematic, dorsal, intra-cardiac view of a fixed heart valved stent in the mitral position according to the invention. Note the good alignment of the valved stent with the left atrial environment. Distances between the left atrial wall/mitral annulus and the valved stent are avoided. Heart valve and anchoring sutures for the ventricular apex have been omitted for simplification.

Claims
  • 1. A heart valve stent, comprising: a self-expanding catheter-inserted stent body section with valve leaflets disposed therein and self-expanding atrial retaining braces for atrial anchoring located at a proximal end of said stent body section said atrial retaining braces comprising a retaining skirt of a plurality of radial tooth-like projections circumferentially disposed around the proximal end of the stent body section, said tooth-like projections having a serrated, arched or triangular shape and extending radially outward from the proximal end of said stent body section at an angle bent away from the stent body section, said projections covered with a sealing membrane; and at least one ventricular anchoring suture attached to a distal end of said stent body section.
  • 2. The heart valve stent of claim 1, further comprising wherein the ventricular anchoring suture is adjustable.
  • 3. The heart valve stent of claim 1, further comprising wherein the heart valve implant is integrated within the lumen of the stent body section near or at the proximal end of the stent body section.
  • 4. The heart valve stent of claim 3, wherein the heart valve implant further comprises one of the group of a circular, oval-shaped and u-shaped annulus.
  • 5. The heart valve stent of claim 3, further comprising wherein the heart valve implant is a mitral valve.
  • 6. The heart valve stent of claim 3, further comprising wherein the heart valve implant is a tricuspid valve.
  • 7. The heart valve stent of claim 3, further comprising a sealing membrane between the heart valve implant and the stent.
  • 8. The heart valve stent of claim 1, wherein the stent body is further comprised of a cross-hatching of metal wire, including but not limited to the group of diamond-shaped hatching, loop-shaped hatching, or a similar pattern.
  • 9. The heart valve stent of claim 8, further comprising wherein the wire is made from a shape memory alloy.
  • 10. The heart valve stent of claim 8, wherein the stent body is foldable and self-expanding.
  • 11. A heart valve stent, shaped as a truncated cone, comprising: a foldable, self-expanding stent body section with a heart valve implant, wherein the stent body section is comprised of a cross-hatching of metal wire made from a shape memory alloy, including but not limited to the group of diamond-shaped hatching, loop-shaped hatching, or a similar pattern; self-expanding atrial retaining braces for atrial anchoring located at a proximal end of said stent body section, said atrial retaining braces comprising a retaining skirt of a plurality of radial tooth-like projections circumferentially disposed around the proximal end of the stent body section, said tooth-like projections having a serrated, arched or triangular shape and extending radially outward from the proximal end of said stent body section at an angle bent away from the stent body section, said projections covered with a sealing membrane; said heart valve implant integrated within the lumen of the stent body section at or near the proximal end of the stent body section; said heart valve stent further comprising a circular, oval-shaped or u-shaped annulus and either a mitral valve or a tricuspid valve; and, at least one ventricular anchoring suture; and wherein the ventricular anchoring suture is adjustable.
Priority Claims (1)
Number Date Country Kind
10 2007 043 830 Sep 2007 DE national
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/677,958, filed Sep. 9, 2010, (now abandoned), which claims priority under 35 U.S.C. §371 to, and is a U.S. national phase entry of, PCT/DE2008/001515, filed Sep. 10, 2008, which claims priority to German application no. 10 2007 043 830.5, filed Sep. 13, 2007, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (297)
Number Name Date Kind
3409013 Berry Nov 1968 A
3548417 Kisher Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4626255 Weinhold Dec 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4829990 Thuroff et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5639274 Fischell et al. Jun 1997 A
5665115 Cragg Sep 1997 A
5697905 Ambrosio Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5741333 Frid Apr 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein May 1998 A
5769812 Stevens et al. Jun 1998 A
5800508 Goicoechea et al. Sep 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler Jan 1999 A
5855602 Angell Jan 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5993481 Marcade et al. Nov 1999 A
6027525 Suh et al. Feb 2000 A
6045497 Schweich, Jr. et al. Apr 2000 A
6077214 Mortier et al. Jun 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6183411 Mortier et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6260552 Mortier et al. Jul 2001 B1
6261222 Schweich, Jr. et al. Jul 2001 B1
6264602 Mortier et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian Oct 2001 B1
6302906 Goecoechea et al. Oct 2001 B1
6332893 Mortier et al. Dec 2001 B1
6350277 Kocur Feb 2002 B1
6358277 Duran Mar 2002 B1
6402679 Mortier et al. Jun 2002 B1
6402680 Mortier et al. Jun 2002 B2
6425916 Garrison et al. Jul 2002 B1
6440164 Di Matteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Balley et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6537198 Vidlund et al. Mar 2003 B1
6569196 Vesely et al. May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6605112 Moll Aug 2003 B1
6616684 Vidlund et al. Sep 2003 B1
6622730 Ekvall et al. Sep 2003 B2
6629921 Schweich, Jr. et al. Oct 2003 B1
6652578 Bailey et al. Nov 2003 B2
6709456 Langberg et al. Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6746471 Mortier et al. Jun 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6810882 Langberg et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6893460 Spenser et al. May 2005 B2
6908424 Mortier et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6936067 Buchanan Aug 2005 B2
6955175 Stevens et al. Oct 2005 B2
6974476 McGuckin et al. Dec 2005 B2
6997950 Chawla Feb 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7044905 Vidlund et al. May 2006 B2
7077862 Vidlund et al. Jul 2006 B2
7100614 Stevens et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7112219 Vidlund et al. Sep 2006 B2
7141064 Scott et al. Nov 2006 B2
7175656 Khairkhahan Feb 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7247134 Vidlund et al. Jul 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7316706 Bloom et al. Jan 2008 B2
7329278 Seguin et al. Feb 2008 B2
7374571 Pease et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7404824 Webler Jul 2008 B1
7416554 Lam et al. Aug 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7503931 Kowalsky et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513908 Lattouf Apr 2009 B2
7524330 Berreklouw Apr 2009 B2
7556646 Yang et al. Jul 2009 B2
7585321 Cribier Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7632308 Loulmet Dec 2009 B2
7674222 Nikolic et al. Mar 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7766961 Patel et al. Aug 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7837727 Goetz et al. Nov 2010 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7942928 Webler et al. May 2011 B2
7955247 Levine et al. Jun 2011 B2
7955385 Crittenden Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7988727 Santamore et al. Aug 2011 B2
8043368 Crabtree Oct 2011 B2
8052749 Salahieh Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8109996 Stacchino Feb 2012 B2
8167934 Styrc et al. May 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8226711 Mortier et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
20020139056 Finnell Oct 2002 A1
20030010509 Hoffman Jan 2003 A1
20030078652 Sutherland Apr 2003 A1
20040064014 Melvin et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040127983 Mortier et al. Jul 2004 A1
20040152947 Schroeder et al. Aug 2004 A1
20040163828 Silverstein et al. Aug 2004 A1
20050004652 Van der Burg et al. Jan 2005 A1
20050075727 Wheatley Apr 2005 A1
20050096498 Houser et al. May 2005 A1
20050113810 Houser et al. May 2005 A1
20050113811 Houser et al. May 2005 A1
20050121206 Dolan Jun 2005 A1
20050125012 Houser et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050240200 Bergheim Oct 2005 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060042803 Gallaher Mar 2006 A1
20060161040 McCarthy et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060241745 Solem Oct 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070050020 Spence Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070073387 Forster et al. Mar 2007 A1
20070078297 Rafiee et al. Apr 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118151 Davidson May 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070215362 Rodgers Sep 2007 A1
20070221388 Johnson Sep 2007 A1
20070256843 Pahila Nov 2007 A1
20070267202 Mariller Nov 2007 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20090076598 Salahieh et al. Mar 2009 A1
20090082619 De Marchena Mar 2009 A1
20090099410 De Marchena Apr 2009 A1
20090112309 Jaramillo Apr 2009 A1
20090132035 Roth et al. May 2009 A1
20090137861 Goldberg et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090234318 Loulmet et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248149 Gabbay Oct 2009 A1
20090276040 Rowe Nov 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090326575 Galdonik et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100021382 Dorshow et al. Jan 2010 A1
20100192402 Yamaguchi et al. Aug 2010 A1
20100217382 Chau Aug 2010 A1
20110112632 Chau May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137408 Bergheim Jun 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120035722 Tuval Feb 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120215303 Quadri et al. Aug 2012 A1
Foreign Referenced Citations (77)
Number Date Country
1001074 May 1955 DE
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10010074 Oct 2001 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
102006052564 Dec 2007 DE
0103546 Mar 1984 EP
0144167 Jun 1985 EP
0597967 Dec 1994 EP
0592410 Oct 1995 EP
0850607 Jul 1998 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1 264 582 Dec 2002 EP
1469797 Oct 2004 EP
1570809 Sep 2005 EP
1653888 May 2006 EP
2 055 266 May 2009 EP
2 055 266 May 2009 EP
2815844 May 2002 FR
2788217 Jul 2007 FR
2056023 Mar 1981 GB
1 017 275 Aug 2002 NL
1271508 Nov 1986 SU
WO9117720 Nov 1991 WO
WO9217118 Oct 1992 WO
WO9301768 Feb 1993 WO
WO9724080 Jul 1997 WO
WO9829057 Jul 1998 WO
WO9933414 Jul 1999 WO
WO9940964 Aug 1999 WO
WO9947075 Sep 1999 WO
WO0018333 Apr 2000 WO
WO0041652 Jul 2000 WO
WO 0044313 Aug 2000 WO
WO0047139 Aug 2000 WO
WO0135878 May 2001 WO
WO0149213 Jul 2001 WO
WO0154624 Aug 2001 WO
WO0154625 Aug 2001 WO
WO 0156512 Aug 2001 WO
WO 0161289 Aug 2001 WO
WO0162189 Aug 2001 WO
WO0164137 Sep 2001 WO
WO0176510 Oct 2001 WO
WO0222054 Mar 2002 WO
WO0236048 May 2002 WO
WO0241789 May 2002 WO
WO0243620 Jun 2002 WO
WO0247575 Jun 2002 WO
WO0249540 Jun 2002 WO
WO 02076348 Oct 2002 WO
WO03003943 Jan 2003 WO
WO03003949 Jan 2003 WO
WO03037227 May 2003 WO
WO03047468 Jun 2003 WO
WO2004019825 Mar 2004 WO
WO2005087140 Sep 2005 WO
WO2006014233 Feb 2006 WO
WO2006034008 Mar 2006 WO
WO2006135536 Dec 2006 WO
WO2008005405 Jan 2008 WO
WO2008009940 Jan 2008 WO
WO2008035337 Mar 2008 WO
WO2008125906 Oct 2008 WO
WO2008147964 Dec 2008 WO
WO2008150529 Dec 2008 WO
WO2009024859 Feb 2009 WO
WO2009-026272 Feb 2009 WO
WO2009033469 Mar 2009 WO
WO2011163275 Dec 2011 WO
Non-Patent Literature Citations (59)
Entry
Ma L., et al., Double-crowned valved stents for off-pump mitral valve replacement. Eur J Cardiothorac Surg. Aug. 2005, 28(2): 194-198.
Doudjemline Y., et al., Steps toward the percutaneous replacement of atrioventricular valves an experiemental study. J. Am. Coll. Cardiol. Jul. 19, 2005; 46(2): 360-365.
International Search Report from International Application No. PCT/US2009/041754 dated Sep. 25, 2009.
U.S. Appl. No. 13/350,310, filed Jan. 13, 2012, Rowe.
U.S. Appl. No. 13/356,136, filed Jan. 23, 2012, Chau.
C. Orton, “Mitralseal: Hybrid Transcatheter Mitral Valve Replacement,” www.acvs.org/symposium/proceedings2011/data/papers/102.pdf, pp. 311, 312.
Liang Ma, et al., “Double-Crowned Valve Stents for Off-Pump Mitral Valve Replacement,” European Journal of Cardio-Thoracic Surgery, 2005, vol. 28, pp. 194-199.
Lutter, Georg, et al., “Mitral Valved Stent Implantation,” European Journal of Cardio-Thoracic Surgery, 2010, vol. 38, pp. 350-355.
Lozonschi, Lucian, “Transapical Mitral Valved Stent Implantation: A Survival Series in Swine,” The Journal of Thoracic and Cardiovascular Surgery, Aug. 2010, vol. 140, Issue 2, pp. 422-426.
M. Tofeig, et al., “Transcatheter Closure of Mid-Muscular Ventricular Septal Defect with an Amplatzer VSD Occluder Device,” Heart, vol. 81, 1999, pp. 438-440.
Ma L., et al., “Double-Crowned Valved Stents for Off-Pump Mitral Valve Replacement,” Eur J Cardiothorac Surg. Aug. 2005, vol. 28, No. 2, pp. 194-198.
Boudjemline Y., et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves an Experimental Study,” J. A. Coll. Cardiol. Jul. 19, 2005, vol. 46, No. 2, pp. 360-365.
Andersen, Henning Rud, “History of Percutaneous Aortic Valve Prosthesis,” Herz 34 2009 Nr. 5, Urban & Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.
Almagor, M.D., Yaron, et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, vol. 16, No. 6, pp. 1310-1314, Nov. 1, 1990; ISSN 0735-1097.
Sabbah, Ph.D., Hani N., et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989; ISSN 0886-0440.
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Kolata, Gina, “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” nytimes.com , httol/www.nytimes.com/1991/01/03/healthidevice-that-opens-clogged-arteries-oets-a-faili . . . , Jul. 29, 2009, 2 pages.
Urban, M.D., Philip, “Coronary Artery Stenting,” Editions Modecine et Hygiene, Geneve, 1991, pp. 5-47.
Al-Khaja, N., et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, vol. 3, pp. 305-311, Jun. 30, 2009.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, ButtenNorths 1986.
Benchimol, Alberto, et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977, vol. 273, No. 1, pp. 55-62.
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, pp. 227-230.
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538.
Inoune, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery, vol. 87, pp. 394-402, 1984.
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenos's,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Lawrence, Jr., M.D., David D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology 1897, 163, pp. 357-360.
Dotter, M.D., Charles T., “Transluminal Treatment of Arteriosclerotic Obstruction,” University of Oregon's Minthorn Memorial Laboratory for Cardiovascular Research through Radiology, Circulation, vol. XXX, Nov. 1964, pp. 654-670.
Sigwart, Ulrich, “An Overview of Intravascular Stents: Old and New,” Chapter 48, Textbook of Interventional Cardiology, 2nd Edition, W. B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Rashkind, M.D., William J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367.
Rosch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radio, 2003, 14, pp. 841-853.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Ross, F.R.C.S., DA., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, approximately 1968.
Rashkind, M.D., William J., “Creation of an Atrial Septa Defect Withoput Thoracotomy,” Journal of the American Medical Association, vol. 196, No. 11, Jun. 13, 1966, pp. 173-174.
Porstmann, W., et al., “Der VerschluB des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskulare Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203.
Curriculum Vitae of Robert A. Ersek, M.D., FACS, Jul. 10, 2009, http://1Atomi.ersek.com/rae-cv.htm.
International Search Report from corresponding PCT case No. PCT/US2010/058860, dated Aug. 25, 2011.
Buckberg, Gerald, et al., “Restoring Papillary Muscle Dimensions During Restoration in Dilated Hearts,” Interactive Cardiovascular and Thoracic Surgery, 2005, vol. 4, pp. 475-477.
International Search Report and Written Opinion from corresponding International Patent Application PCT/US2012/050579, dated Feb. 26, 2013.
H. R. Andersen et al., “Transluminal Implantation of Artificial Heart Valves: Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs,” European Heart Journal, 1992, Issue 5, vol. 13, pp. 704-708.
Henning Rud Andersen, “Transluminal Catheter Implanted Prosthetic Heart Valves,” International Journal of Angiology, 1998, Issue 2, vol. 7, pp. 102-106.
L. L. Knudsen et al., “Catheter-Implanted Prosthetic Heart Valves. Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs,” International Journal of Artificial Organs, 1993, Issue 5, vol. 16, pp. 253-262.
Nader Moazami et al., “Transliminal Aortic Valve Placement: A Feasibility Study With a Newly Designed Collapsible Aortic Valve,” ASAIO Journal, Sep./Oct. 1996, Issue 5, vol. 42, pp. M381-M385.
Robert C. Ashton Jr., “Development of an Intraluminal Device for the Treatment of Aortic Regurgitation: Prototype and in Vitro Testing System,” Journal of Thoracic and Cardiovascular Surgery, 1996, Issue/vol. 112, pp. 979-983.
A. P. Yoganathan et al., “The Current Status of Prosthetic Heart Valves, Polymetric Materials and Artificial Organs,” American Chemical Society , Mar. 20, 1983, pp. 111-150.
Ellis Greenhalgh et al., “Design and Characterization of a Biometric Prosthetic Aortic Heart Valve,” North Carolina State University.1994, p. 137.
Gary Chamberlain, “Ceramics Replace Body Parts,” Design News, Jun. 9, 1997, Issue 11, vol. 52.
M. Tofeig, et al., “Transcatheter Closure of a Mid-Muscular Ventricular Septal Defect with an Amplatzer VSD Occluder Device,” Heart, vol. 81, 1999, pp. 438-440.
E. P. M. Roussea et al., “A Mechanical Analysis of the Closed Hancock Heart Valve Prosthesis,” Journal of Biomechanics, 1998, Issue 7, vol. 21, pp. 545-562.
C. Orton, “Mitralseal: Hybrid Transcatheter Mitral Valve Replacement,” Respiratory and Thoracic Surgery, Symposium: Small Animal Proceedings, 2011, pp. 311-312.
G. M. Bernacca, et al., “Polyurethane Heart Valves: Fatigue Failure, Calcification, and Polyurethane Structure,” Journal of Biomedical Materials Research, Mar. 5, 1997, Issue 3, vol. 34, pp. 371-379.
Kevin Drawbaugh, “Feature—Heart Surgeons Explore Minimally Invasive Methods,” Reuters, Jul. 16, 1996.
Shape Memory Alloys, ttp://webdocs.cs.ualberta.ca/˜database; Nov. 14, 2012, pp. 1-3.
Gray, Gray's Anatomy of the Body, 1974, pp. ?(1-7), 474-479, 497-498.
Reul, et al., “The Geometry of the Aortic Root in Health, at Valve Disease and After Valve Replacement,” Biomechanics, vol. 23, No. 2, 1990, pp. 181-191.
Choo, et al., “Aortic Root Geometry: Pattern of Differences Between Leaflets and Sinuses of Valsava,” ICR Publisher, 1999.
Jin, et al., “Aortic Root Geometry and Stentless Porcine Valve Competence,” Seminars in Thoracic and Cardiovascular Surger, vol. 11, No. 4, Suppl. 1, Oct. 1999, pp. 145-150.
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” American Heart Association, Inc., 2006; pp. 841-850.
Declaration of Malcolm J. R. Dalrymple-Hay, Nov. 9, 2012, pp. 1-11; with Curriculum Vitae, Oct. 4, 2012.
Related Publications (1)
Number Date Country
20120035713 A1 Feb 2012 US
Continuations (1)
Number Date Country
Parent 12677958 US
Child 13275683 US